Articles: ninos.
-
This study compares pregnancy outcomes, including rates of stillbirth (fetal death ≥24 weeks’ gestation), preterm and cesarean delivery, and neonatal unit admission in the months preceding vs during the 2020 COVID-19 pandemic at a London university hospital.
-
Interleukin 1 (IL-1) is a potential target of therapy in COVID-19 during the severe respiratory-inflammatory phase ("cytokine release syndrome"), when pulmonary macrophages are hyperactivated, releasing IL-1 and other cytokines. Preliminary evidence indicates that anakinra and canakinumab, drugs that block the action of IL-1 and have a good safety profile, improve the outcomes of patients with COVID-19 cytokine release syndrome. Results from large, randomized clinical trials are pending.